Actavis Said to Have Spurned $15 Billion Offer

REPLAY VIDEO
Your next video will start in
Pause
  • Info

  • Comments

May 14 (Bloomberg) -- Actavis rejected a cash-and-stock offer from fellow generic drugmaker Mylan for $15 billion, deciding instead to pursue talks to take over Warner Chilcott, said people familiar with the matter. Bloomberg's Jeff McCracken reports on Bloomberg Television's "Street Smart." (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change